Get the Stockscreener App
17.52
1.57%
-0.28
After Hours:
17.53
0.01
+0.06%
Viridian Therapeutics Inc stock is traded at $17.52, with a volume of 662.20K.
It is down -1.57% in the last 24 hours and up +25.32% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
See More
Previous Close:
$17.80
Open:
$17.55
24h Volume:
662.20K
Relative Volume:
0.90
Market Cap:
$1.43B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-4.1224
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
+0.17%
1M Performance:
+25.32%
6M Performance:
-9.60%
1Y Performance:
+3.98%
1-Day Range:
$17.38
$17.93
1-Week Range:
$16.65
$18.80
52-Week Range:
$9.90
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
17.52 | 1.45B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
What are the latest earnings results for Viridian Therapeutics Inc.Earnings Report Outlook For 2025 - jammulinksnews.com
Is it the right time to buy Viridian Therapeutics Inc. stockSwing Trade Outlook For Every Investor - jammulinksnews.com
Why is Viridian Therapeutics Inc. stock attracting strong analyst attentionSwing Trade Growth Plan With High Returns - jammulinksnews.com
When is Viridian Therapeutics Inc. stock expected to show significant growthSwing Trade Report For Consistent Profits - jammulinksnews.com
How strong is Viridian Therapeutics Inc. company’s balance sheetAI Powered Strategy For Beginners - jammulinksnews.com
What makes Viridian Therapeutics Inc. stock price move sharplyMarket Momentum and Signal Alerts Suggest Reversal - metal.it
Viridian grants Kissei rights to veligrotug and VRDN-003 in Japan - The Pharma Letter
Published on: 2025-07-30 17:28:02 - metal.it
Viridian Therapeutics' Strategic Expansion in Japan: A Game-Changer for TED Treatment and Shareholder Value - AInvest
Viridian partners with Japanese firm for Veligrotug and VRDN-003 - Seeking Alpha
Viridian Therapeutics and Kissei Pharma ink deal worth $315 M focusing on thyroid eye disease in Japan - BioSpectrum Asia
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments - Business Wire
What data driven models say about Viridian Therapeutics Inc.’s futureFree Fundamental Winners With Safe Entry Plan - Newser
Real time social sentiment graph for Viridian Therapeutics Inc.Free Chart Breakout Buy Signal Detection - Newser
What is the dividend policy of Viridian Therapeutics Inc. stockRecord-breaking capital gains - jammulinksnews.com
Bank of New York Mellon Corp Grows Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
What institutional investors are buying Viridian Therapeutics Inc. stockSuperior returns - jammulinksnews.com
What is Viridian Therapeutics Inc. company’s growth strategyTremendous growth opportunities - jammulinksnews.com
Competitive Positioning of Viridian Therapeutics Inc.: Is It Leading or LaggingProtected Capital Trading Plan - metal.it
How does Viridian Therapeutics Inc. compare to its industry peersGet real-time alerts on high-potential stocks - jammulinksnews.com
Intrinsic Value of Viridian Therapeutics Inc. Stock: Is It Undervalued or OvervaluedFree Stock Selection with 300% Return - Newser
Insider Buying and Strategic Alignment at Viridian Therapeutics: A Signal for Biotech Investors - AInvest
Viridian Therapeutics Inc. Stock Support and Resistance Levels You Should Know - Newser
Key External Factors That Drive Viridian Therapeutics Inc. Stock Price MovementsDaily Gain Forecast - Newser
Viridian Therapeutics Insiders Added US$616.3k Of Stock To Their Holdings - Yahoo Finance
What drives Viridian Therapeutics Inc. stock priceFree Stock Movement Tracking - PrintWeekIndia
Viridian Therapeutics Inc. Stock Analysis and ForecastTremendous return rates - Autocar Professional
What analysts say about Viridian Therapeutics Inc. stockLightning-fast growth - PrintWeekIndia
How Viridian Therapeutics Inc. stock performs during market volatilityMarket Ready Callouts - Newser
Is Viridian Therapeutics Inc. a good long term investmentExplosive trading opportunities - Autocar Professional
Viridian Therapeutics’ Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial - MSN
Why Viridian Therapeutics Inc. stock attracts strong analyst attentionBreakout Level Watch - Newser
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):